Pioglitazone Decreases Plasma Angiotensin II Concentration in Type 2 Diabetes

作者：Saiki Atsuhito; Ohira Masahiro; Endo Kei; Koide Nobukiyo; Oyama Tomokazu; Murano Takeyoshi; Miyashita Yoh^*; Shirai Kohji

来源：Journal of Atherosclerosis and Thrombosis, 2010, 17(6): 651-657.

DOI：10.5551/jat.4002

• Angiotensin.
• Pioglitazone
• Insulin resistance
• Lipoprotein lipase

Aim: Adipocytes express all components of the renin-angiotensin system (RAS), and adipocyte RAS regulates adipocyte differentiation and metabolism. Plasma angiotensin. (A II) is a putative marker of adipocyte RAS production. The aim of this study was to investigate the effect of pioglitazone on plasma A. in type 2 diabetes (T2D).
Methods: Fifty Japanese subjects with T2D were randomly allocated to two groups. One group was administered pioglitazone 30 mg/day (pioglitazone group) and the other group was not given pioglitazone (control group) for 16 weeks. Lipoprotein lipase mass in preheparin serum (LPL mass) was measured as an adipocyte-derived factor and a marker of insulin sensitivity.
Results: In the pioglitazone group, the mean HbA1c decreased (p<0.0001), LPL mass increased (p<0.0001), and plasma A II decreased (p = 0.0007), whereas these parameters were unchanged in the control group. The change in plasma A II correlated negatively with the change in LPL mass (r = -0.312) in the pioglitazone group. In the pioglitazone group, the decrease in plasma A II was higher (p = 0.0002) and the increase in LPL mass tended to be higher (p = 0.0941) in the subgroup with higher baseline plasma A II than that with lower plasma A II.
Conclusions: The present study indicates that pioglitazone decreases plasma A II associated with an increase in LPL mass in T2D. The insulin-sensitizing effect of pioglitazone may be involved in suppressing adipocyte RAS.

• 出版日期2010